| K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ... New England Journal of Medicine 359 (17), 1757-1765, 2008 | 4006 | 2008 |
| Cetuximab for the treatment of colorectal cancer DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ... New England Journal of Medicine 357 (20), 2040-2048, 2007 | 2173 | 2007 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 2050 | 2016 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1460 | 2012 |
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … M Peeters, T Jay Price JOURNAL OF CLINICAL ONCOLOGY, 2010 | 1082 | 2010 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ... Science translational medicine 8 (346), 346ra92-346ra92, 2016 | 791 | 2016 |
| Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer DG Haller, J Tabernero, J Maroun, F De Braud, T Price, E Van Cutsem, ... J Clin Oncol 29 (11), 1465-1471, 2011 | 740 | 2011 |
| The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ... Nature 575 (7781), 217-223, 2019 | 604 | 2019 |
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced … P Ross, M Nicolson, D Cunningham, J Valle, M Seymour, P Harper, ... Journal of clinical oncology 20 (8), 1996-2004, 2002 | 604 | 2002 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... Journal of clinical oncology 28 (19), 3191-3198, 2010 | 446 | 2010 |
| Management of gastric cancer in Asia: resource-stratified guidelines L Shen, YS Shan, HM Hu, TJ Price, B Sirohi, KH Yeh, YH Yang, T Sano, ... The Lancet Oncology 14 (12), e535-e547, 2013 | 418 | 2013 |
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non … TJ Price, M Peeters, TW Kim, J Li, S Cascinu, P Ruff, AS Suresh, ... The Lancet Oncology 15 (6), 569-579, 2014 | 399 | 2014 |
| Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients HJ Schmoll, T Cartwright, J Tabernero, MP Nowacki, A Figer, J Maroun, ... Journal of Clinical Oncology 25 (1), 102-109, 2006 | 364 | 2006 |
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer E Van Cutsem, YJ Bang, F Feng-Yi, JM Xu, KW Lee, SC Jiao, JL Chong, ... Gastric Cancer 18 (3), 476-484, 2015 | 271 | 2015 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 263 | 2020 |
| Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced … TJ Price, JE Hardingham, CK Lee, A Weickhardt, AR Townsend, JW Wrin, ... J Clin Oncol 29 (19), 2675-2682, 2011 | 221 | 2011 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 215 | 2017 |
| Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase … HJ Schmoll, J Tabernero, J Maroun, F De Braud, T Price, E Van Cutsem, ... Journal of Clinical Oncology 33 (32), 3733-3740, 2015 | 208 | 2015 |
| Colorectal cancer: Metastases to a single organ S Vatandoust, TJ Price, CS Karapetis World journal of gastroenterology 21 (41), 11767, 2015 | 186 | 2015 |
| Final results from a randomized phase 3 study of FOLFIRI±panitumumab for second-line treatment of metastatic colorectal cancer M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ... Annals of Oncology 25 (1), 107-116, 2014 | 180 | 2014 |
Dongsheng TuProfessor of Biostatistics, Queen's University at Kingston, CanadaDirección de correo verificada de ctg.queensu.ca
